A PYMNTS Company

Appeals Court Revives Regeneron’s Antitrust Lawsuit Against Novartis Over Vision Treatment

By  |  March 18, 2024
Novartis

The 2nd US Circuit Court of Appeals in Manhattan has breathed new life into an antitrust lawsuit brought by Regeneron Pharmaceuticals against Novartis. The lawsuit centers around prescription treatments aimed at addressing a condition that can result in severe eye disorders, potentially leading to permanent blindness.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    Subscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    The decision, rendered on Monday, marked a pivotal moment in the ongoing legal battle between the pharmaceutical giants. The appeals court ruled that a lower court judge had erred in dismissing Regeneron’s lawsuit, citing the incorrect application of legal standards to the claims put forth by the plaintiff.

    We’d love to be your preferred source for news.

    Please add us to your preferred sources list so our news, data and interviews show up in your feed. Thanks!

    Add as Preferred Source

    The dispute between Regeneron and Novartis underscores the high stakes involved in the development and commercialization of treatments for critical medical conditions. At the heart of the lawsuit are allegations of anticompetitive behavior by Novartis, aimed at stifling competition and maintaining a dominant position in the market for prescription therapies targeting the identified eye disorder.

    Read more: Paris Appeals Court Overturns Novartis, Roche $475M Antitrust Fine

    The precise nature of the alleged antitrust violations has not been fully disclosed, but Regeneron’s contentions suggest a concerted effort by Novartis to undermine competition and impede the market entry of rival treatments. Such tactics, if proven, could have far-reaching implications for the pharmaceutical industry, particularly in the realm of specialized medications addressing complex medical needs.

    Source: Reuters